Assessing Preferences of Patients with Chronic Spontaneous Urticaria for Injectable Treatment Profiles

Ana Maria Giménez-Arnau (), Maria-Magdalena Balp, Andrii Danyliv, Tonya Winders, James O’Donoghue, Jörn Kleebach, Samantha Morrison, Shaun Walsh, Maike Mueller, Daniela Lopez-Ortiz, Marcus Maurer and Jonathan A. Bernstein
Additional contact information
Ana Maria Giménez-Arnau: Hospital del Mar Research Institute, IMIM, Universitat Pompeu Fabra
Maria-Magdalena Balp: Novartis Pharma AG
Andrii Danyliv: Novartis Pharma AG
Tonya Winders: Global Allergy & Airways Patient Platform
James O’Donoghue: Ipsos SA
Jörn Kleebach: Ipsos SA
Samantha Morrison: Ipsos
Shaun Walsh: Novartis Global Service Center
Maike Mueller: Novartis Pharma GmbH
Daniela Lopez-Ortiz: Novartis Farmacéutica S. A.
Marcus Maurer: Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin
Jonathan A. Bernstein: University of Cincinnati College of Medicine

The Patient: Patient-Centered Outcomes Research, 2025, vol. 18, issue 2, No 8, 173-185

Abstract: Abstract Background In the context of injectable biologic products approved or in development for chronic spontaneous urticaria (CSU), it is important to capture which treatment attributes matter most to patient and what trade-offs patients are willing to make. Objectives The CHOICE-CSU study aimed to quantify patient preferences toward injectable treatment attributes among patients with CSU, inadequately controlled by H1-antihistamines. Methods This was a two-phase cross-sectional patient preference study in adult patients with a diagnosis of CSU, inadequately controlled by H1-antihistamines. A qualitative phase collected patients’ insights and relevant treatment attributes that mattered to them, and the outputs were used for the quantitative phase to create the actual injectable treatment profiles with attributes and levels such as: efficacy, safety, and mode of administration. The quantitative phase used discrete choice experiment (DCE) methodology. Eligible patients were asked to make hypothetical choices between 12 treatment profile pairs, created by Sawtooth SoftwareTM. The DCE data were analyzed using hierarchical Bayesian logistic regression models, enabling the quantification of the relative importance of each attribute/level during the decision-making process. Results A total of 450 respondents participated in the DCE. The key attributes driving respondent preference amongst injectable treatment options were type of administration device (relative importance 18.5%), complete control of urticaria (relative importance 17.4%), and resolution of angioedema (relative importance 16.4%). Keeping all other attributes and levels equal, the predicted choice share was higher for a profile with an auto-injector versus one with a pre-filled syringe (72.9% versus 27.1%). Conclusions The CHOICE-CSU study is the first study to provide a quantitative assessment of preferences that patients with CSU, inadequately controlled by H1-antihistamines, have for injectable treatment attributes. Symptom-free periods are the most important overriding therapy goal for patients, and patients will accept some inconveniences, such as administration mode, to achieve this. Additionally, when efficacy is equivalent, administration ease of injectable therapies is valued by patients. As new CSU oral treatment options emerge, additional testing of patient preference toward oral treatments will be required.

Date: 2025
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40271-024-00725-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:patien:v:18:y:2025:i:2:d:10.1007_s40271-024-00725-3

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40271

DOI: 10.1007/s40271-024-00725-3

Access Statistics for this article

The Patient: Patient-Centered Outcomes Research is currently edited by Christopher I. Carswell

More articles in The Patient: Patient-Centered Outcomes Research from Springer, International Academy of Health Preference Research
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().